Search / Trial NCT00002039

An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients

Launched by ASTRA USA · Aug 30, 2001

Trial Information

Current as of December 06, 2024

Completed

Keywords

Retinitis Aids Related Opportunistic Infections Drug Therapy, Combination Foscarnet Cytomegalovirus Infections Acquired Immunodeficiency Syndrome Antiviral Agents Zidovudine

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following are excluded:
  • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
  • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic and/or hypertensive retinopathy.
  • Known allergy to foscarnet.
  • Recurrent episode of cytomegalovirus (CMV) retinitis.
  • Concurrent Medication:
  • Excluded:
  • Nephrotoxic drugs.
  • Patients with the following are excluded:
  • Recurrent episode of cytomegalovirus (CMV) retinitis.
  • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
  • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic, and/or hypertensive retinopathy.
  • Known allergy to foscarnet.
  • Prior Medication:
  • Excluded:
  • Ganciclovir for cytomegalovirus (CMV) retinitis.
  • Foscarnet for CMV retinitis.
  • Patients with AIDS as defined by the CDC with manifest first episode cytomegalovirus (CMV) retinitis, as identified by its characteristic ophthalmoscopic appearance and verified by fundus photography.
  • Patients must be able to give informed consent.

About Astra Usa

Astra USA, a subsidiary of AstraZeneca, is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines that address unmet medical needs across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. With a strong commitment to advancing healthcare, Astra USA leverages cutting-edge science and technology to deliver high-quality treatments and improve patient outcomes. The organization emphasizes collaboration with healthcare professionals, regulatory bodies, and patient communities to ensure the safety and efficacy of its clinical trials, ultimately striving to enhance the quality of life for patients globally.

Locations

Houston, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials